Del Nido Cardioplegia Versus Cold Blood Cardioplegia in Adult Cardiac Surgery: Protocol for a Randomized Controlled Trial

Jessica Garcia-Suarez, Javier Garcia Fernandez, Sergio Sanz, Daniel Martinez Lopez, Leticia Reques, Alberto Forteza Gil, Jessica Garcia-Suarez, Javier Garcia Fernandez, Sergio Sanz, Daniel Martinez Lopez, Leticia Reques, Alberto Forteza Gil

Abstract

Background: The use of cardioplegia solutions as a myocardial protection technique is essential during cardiac surgery with cardiopulmonary bypass. The del Nido cardioplegia solution (DNS) has been widely used as a myocardial preservation technique for pediatric patients undergoing cardiac surgery with cardiopulmonary bypass. Its unique pharmacological features have created growing interest for adult cardiac surgery, especially for elderly patients or those with ventricular dysfunction who are more prone to ischemia-reperfusion injury. Ever since its implementation, several retrospective studies have been published to validate the efficacy, safety, and efficiency of DNS in adult patients undergoing coronary revascularization, valve replacement, or combined procedures. Recently, a meta-analysis based on nine retrospective studies was published claiming the noninferiority of DNS compared to other conventional cardioplegia solutions. Few prospective randomized studies have been conducted whose primary outcome was the assessment of DNS clinical efficacy compared to other solutions commonly used in adult patients.

Objective: The aim of this randomized clinical trial is to assess the benefits of DNS compared to Cardi-Braun blood cardioplegia solution in clinical and biochemical terms regarding myocardial protection during adult cardiac surgery.

Methods: This is the protocol of a controlled, randomized, single-center clinical trial carried out at the Puerta de Hierro Majadahonda University Hospital in Spain. A total of 474 participants over the age of 18 years undergoing elective cardiac surgery with cardiopulmonary bypass will be assigned to groups by simple randomization to receive either DNS or Cardi-Braun blood cardioplegia solution. The primary outcome will be the differences between groups in myocardial protection in biochemical terms (ie, perioperative troponin levels) and clinical terms (ie, presence of the composite variable acute cardiovascular event). The clinical trial will be carried out under conditions of respect for the fundamental rights of the person and the ethical principles that affect biomedical research with human beings, as well as in accordance with international recommendations contained in the Declaration of Helsinki and its subsequent revisions.

Results: The inclusion process started in 2018. Data cleaning and analyses are expected to take place in the fall of 2020 and the results are expected in January 2021.

Conclusions: This study is particularly relevant as it will be one of the first to analyze the clinical effects of del Nido cardioplegia on the basis of direct myocardial protection parameters. In light of published studies, carrying out prospective studies based on primary clinical objectives with a larger sample, high-risk patients, and longer cardiopulmonary bypass times continues to be necessary. We believe that our study addresses an important gap in the knowledge of del Nido cardioplegia in adult patient cardiac surgery and will be able to clarify the possible benefits of this method in a large population of patients undergoing these procedures.

Trial registration: European Union Drug Regulating Authorities Clinical Trials Database (EudraCT) 2017-005144-14; https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005144-14+; ClinicalTrials.gov NCT04094168; https://ichgcp.net/clinical-trials-registry/NCT04094168.

International registered report identifier (irrid): DERR1-10.2196/17826.

Keywords: cardiac surgery; del Nido cardioplegia; myocardial protection.

Conflict of interest statement

Conflicts of Interest: None declared.

©Jessica Garcia-Suarez, Javier Garcia Fernandez, Sergio Sanz, Daniel Martinez Lopez, Leticia Reques, Alberto Forteza Gil. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 14.07.2020.

Figures

Figure 1
Figure 1
CONSORT flow diagram.

References

    1. Melrose DG, Dreyer B, Bentall H, Baker JB. Elective cardiac arrest. Lancet. 1955 Jul 02;266(6879):21–22. doi: 10.1016/s0140-6736(55)93381-x.
    1. Matte GS, del Nido PJ. History and use of del Nido cardioplegia solution at Boston Children's Hospital. J Extra Corpor Technol. 2012 Sep;44(3):98–103.
    1. O'Blenes SB, Friesen CH, Ali A, Howlett S. Protecting the aged heart during cardiac surgery: The potential benefits of del Nido cardioplegia. J Thorac Cardiovasc Surg. 2011 Mar;141(3):762–770. doi: 10.1016/j.jtcvs.2010.06.004.
    1. Vázquez A, Favieres C, Pérez M, Valera F, Torregrosa S, Doñate L, Heredia T, Bel A, Hernandez C, Schuler M, Berbel A, Blanco O, Sepúlveda P, López E, Montero JA. Del Nido cardioplegia: A safe, effective and cheap myocardial protection strategy [Article in Spanish] Cirugía Cardiovascular. 2015 Nov;22(6):287–293. doi: 10.1016/j.circv.2015.05.003.
    1. Ataka K, Chen D, Levitsky S, Jimenez E, Feinberg H. Effect of aging on intracellular Ca2+, pHi, and contractility during ischemia and reperfusion. Circulation. 1992 Nov;86(5 Suppl):II371–II376.
    1. Guajardo Salinas GE, Nutt R, Rodriguez-Araujo G. Del Nido cardioplegia in low risk adults undergoing first time coronary artery bypass surgery. Perfusion. 2017 Jan;32(1):68–73. doi: 10.1177/0267659116661051.
    1. Yerebakan H, Sorabella RA, Najjar M, Castillero E, Mongero L, Beck J, Hossain M, Takayama H, Williams MR, Naka Y, Argenziano M, Bacha E, Smith CR, George I. Del Nido cardioplegia can be safely administered in high-risk coronary artery bypass grafting surgery after acute myocardial infarction: A propensity matched comparison. J Cardiothorac Surg. 2014 Oct 30;9:141. doi: 10.1186/s13019-014-0141-5.
    1. Sorabella RA, Akashi H, Yerebakan H, Najjar M, Mannan A, Williams MR, Smith CR, George I. Myocardial protection using del Nido cardioplegia solution in adult reoperative aortic valve surgery. J Card Surg. 2014 Jul;29(4):445–449. doi: 10.1111/jocs.12360.
    1. Li Y, Lin H, Zhao Y, Li Z, Liu D, Wu X, Ji B, Gao B. Del Nido cardioplegia for myocardial protection in adult cardiac surgery: A systematic review and meta-analysis. ASAIO J. 2018;64(3):360–367. doi: 10.1097/MAT.0000000000000652.
    1. Ad N, Holmes SD, Massimiano PS, Rongione AJ, Fornaresio LM, Fitzgerald D. The use of del Nido cardioplegia in adult cardiac surgery: A prospective randomized trial. J Thorac Cardiovasc Surg. 2018 Mar;155(3):1011–1018. doi: 10.1016/j.jtcvs.2017.09.146.
    1. Sanetra K, Gerber W, Shrestha R, Domaradzki W, Krzych Ł, Zembala M, Cisowski M. The del Nido versus cold blood cardioplegia in aortic valve replacement: A randomized trial. J Thorac Cardiovasc Surg. 2020 Jun;159(6):2275–2283.e1. doi: 10.1016/j.jtcvs.2019.05.083.
    1. Lazar HL. Del Nido cardioplegia: Passing fad or here to stay? J Thorac Cardiovasc Surg. 2018 Mar;155(3):1009–1010. doi: 10.1016/j.jtcvs.2017.09.126.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다